Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for SESEN BIO, INC. (SESN : NSDQ)
 
 • Company Description   
Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven Biotherapeutics, is based in Massachusetts, United States.

Number of Employees: 35

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.50 Daily Weekly Monthly
20 Day Moving Average: 7,886,894 shares
Shares Outstanding: 199.46 (millions)
Market Capitalization: $99.73 (millions)
Beta: 0.92
52 Week High: $6.04
52 Week Low: $0.37
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 15.18% 29.73%
12 Week -21.24% -13.40%
Year To Date -38.65% -25.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
245 FIRST STREET SUITE 1800
-
CAMBRIDGE,MA 02142
USA
ph: 617-444-8550
fax: 617-858-0911
ir@sesenbio.com http://www.sesenbio.com
 
 • General Corporate Information   
Officers
Thomas R. Cannell - President; Chief Executive Officer
Jay S. Duker - Chair of the Board of Directors
Monica Forbes - Chief Financial Officer
Elly Ryu - Corporate Controller
Carrie L. Bourdow - Director

Peer Information
SESEN BIO, INC. (CORR.)
SESEN BIO, INC. (RSPI)
SESEN BIO, INC. (CGXP)
SESEN BIO, INC. (BGEN)
SESEN BIO, INC. (GTBP)
SESEN BIO, INC. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 817763105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 199.46
Most Recent Split Date: (:1)
Beta: 0.92
Market Capitalization: $99.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.58
Price/Cash Flow: 6.25
Price / Sales: -
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: -100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -9.01
12/31/21 - -68.69
09/30/21 - -155.66
ROA
03/31/22 - -5.30
12/31/21 - -29.74
09/30/21 - -41.67
Current Ratio
03/31/22 - 21.32
12/31/21 - 17.77
09/30/21 - 15.92
Quick Ratio
03/31/22 - 21.32
12/31/21 - 17.77
09/30/21 - 15.92
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - 206.03
12/31/21 - -32.43
09/30/21 - -492.80
Book Value
03/31/22 - 0.87
12/31/21 - 0.86
09/30/21 - 0.82
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©